Related Experiment Video
Updated: May 9, 2026

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
Published on: October 17, 2025
Health status utilities in pediatrics: a systematic review of acute lymphoblastic leukemia
Raphaële R L van Litsenburg1, Annemieke Kunst2, Jaap Huisman3
1Department of Pediatrics, Division of Oncology-Hematology, VU University Medical Center Amsterdam, Amsterdam, the Netherlands (RRLVL, GJLK).
Insights
Measuring health utilities in children with acute lymphoblastic leukemia (ALL) is challenging. This review found methodological issues in utility measurements, impacting cost-utility analyses for pediatric cancer care.
Area of Science:
- Pediatric Oncology
- Health Economics
- Quality of Life Research
Background:
- Assessing health utilities and quality of life in children presents unique challenges due to developmental stages and cognitive abilities.
- Pediatric acute lymphoblastic leukemia (ALL) requires robust methods for utility measurement to inform healthcare decisions.
Purpose of the Study:
- To systematically review methodological issues in utility measurements using the Health Utilities Index (HUI) in pediatric ALL.
- To identify limitations in current utility assessment tools for children undergoing cancer treatment.
- To inform future cost-utility analyses by highlighting areas for improvement in pediatric health state valuation.
Main Methods:
- Systematic review of studies measuring utility scores in pediatric ALL.
- Searched major databases (PubMed, Embase, Cochrane, CINAHL, PsycINFO) from inception to June 2012.
- Included studies reporting utility scores during or after treatment for pediatric ALL.
Main Results:
- Fifteen studies were included, with most exhibiting methodological shortcomings, particularly in study group definition and representativeness.
- Utility scores varied with treatment, generally improving with advancement in treatment or survivorship.
- Proxy respondents were less reliable for subjective health states compared to observable conditions; HUI2 and HUI3 scores were not interchangeable.
Conclusions:
- Most reviewed studies had suboptimal methodology, indicating a need for developmentally appropriate instruments for all pediatric age groups.
- Enhancing sensitivity and responsiveness requires disease-specific domains and greater inclusion of older children and teenagers in health state valuation.
- Robust health state valuation in children is crucial for valid decision-making regarding healthcare intervention financing.
Background:
Measuring utilities and health-related quality of life (HRQL) in children is challenging due to their cognitive abilities and changing developmental stages.
Purpose:
. To identify methodological issues on utility measurements in children, we performed a systematic review on utilities measured with a single instrument, the Health Utilities Index (HUI), in pediatric acute lymphoblastic leukemia (ALL). The secondary goal was to facilitate future cost-utility analyses without the need for time-consuming assessments. Data Sources. PubMed, Embase, Cochrane Library, CINAHL, and PsycINFO were searched from inception to June 2012. Studies had to report on utility scores in pediatric ALL, either on or after treatment, to be included.
Results:
. Fifteen studies were included. Most studies had methodological shortcomings, which mainly concerned
Study Design:
and definition and representativeness of the study group. Utility scores were dependent on treatment variables, and there generally was an improvement in HRQL as treatment or survivorship advanced. In general, proxy-respondents were less reliable for subjective phenomena than for observable conditions. HUI2 and HUI3 scores were not interchangeable. Limitations. Studies may have been missed because no validated search method for utility studies exists, due to language bias or the exclusion of non-peer-reviewed papers.
Conclusions:
. Most studies in this review were methodologically suboptimal. Future developments should focus on including developmentally appropriate items for the whole pediatric age group. Adding disease-specific domains may enhance the sensitivity and responsiveness of instruments. Efforts should be undertaken to elicit valuation of health states from older children and teenagers as much as possible. For now, it remains difficult to make valid and informed decisions on the financing of interventions until health state valuation in children has become more methodologically robust.
Related Concept Videos
Pharmacokinetics in Pediatric Patients: Drug Excretion
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
Pharmacokinetics in Pediatric Patients: Drug Distribution
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

